![]() |
|
|
Vol. 299, Issue 1, 58-66, October 2001
Oklahoma Foundation for Digestive Research Basic Science
Laboratories, Veterans Affairs Medical Center, Oklahoma City, Oklahoma
(B.G.-V.M., K.V.); and Immunology and Hemostasis, Wyeth/Genetics
Institute, Andover, Massachusetts (J.C.K.)
Recombinant human interleukin (rhIL)-11 has anti-inflammatory and
protective effects in models of intestinal mucosal injury. Our aim was
to investigate whether oral treatment with rhIL-11 reverses functional
abnormalities in intestinal muscle contractility resulting from human
leukocyte antigen (HLA)-B27-dependent gut inflammation. Isometric
contractions were studied in jejunal and colonic longitudinal muscles.
Muscle strips were isolated from HLA-B27 transgenic rats with
spontaneous inflammation following treatment with enteric-coated
rhIL-11 multiparticulates (500 µg/kg) or placebo multiparticulates
given orally every 48 h for 2 weeks. Myeloperoxidase (MPO)
activity was measured in intestinal tissue samples and served as an
index of inflammation. Colonic damage was also assessed histologically.
The HLA-B27 rats receiving placebo had chronic diarrhea, and MPO
activity was increased in the jejunum and colon. Intestinal
inflammation was associated with a decreased ability of the muscles to
generate active tension in response to electrical field
stimulation, carbachol, or high KCl. In the jejunum of
placebo-treated HLA-B27 rats, concentration-effect curves for carbachol
were shifted to lower concentrations yielding a higher
EC50. Oral treatment of HLA-B27 rats with rhIL-11
suppressed the symptoms of diarrhea, normalized MPO activity, and
improved the colonic damage score. Simultaneously, neurally mediated
responses were improved and the maximal tension generated by carbachol
or KCl was normalized in the jejunum and colon. The EC50
for carbachol in the jejunum of HLA-B27 rats was also normalized by
rhIL-11 treatment. Our data demonstrate that oral administration of
enteric-coated rhIL-11 suppresses intestinal inflammation and reverses
intestinal smooth muscle dysfunction in HLA-B27 transgenic rats.
This article has been cited by other articles:
![]() |
R. Noronha, H. Akbarali, A. Malykhina, R. D. Foreman, and B. Greenwood-Van Meerveld Changes in urinary bladder smooth muscle function in response to colonic inflammation Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1461 - F1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Z. Shi and S. K. Sarna Transcriptional regulation of inflammatory mediators secreted by human colonic circular smooth muscle cells Am J Physiol Gastrointest Liver Physiol, August 1, 2005; 289(2): G274 - G284. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Venkova, J. C. Keith Jr., and B. G.-V. Meerveld Oral Treatment with Recombinant Human Interleukin-11 Improves Mucosal Transport in the Colon of Human Leukocyte Antigen-B27 Transgenic Rats J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 206 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Harris, L. M. Albert, Y. Leathurby, M. S. Malamas, R. E. Mewshaw, C. P. Miller, Y. P. Kharode, J. Marzolf, B. S. Komm, R. C. Winneker, et al. Evaluation of an Estrogen Receptor-{beta} Agonist in Animal Models of Human Disease Endocrinology, October 1, 2003; 144(10): 4241 - 4249. [Abstract] [Full Text] [PDF] |
||||